Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer

  • Technology appraisal guidance
  • TA285
  • Published: 
Download guidance (PDF)

7 Review of guidance

7.1 The guidance on this technology will be considered for review in June 2016. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
May 2013